Interview with James Lanthier, CEO of Mindset Pharma

In this episode of the Psychedelic Spotlight podcast we chat with James Lanthier, CEO of Mindset Pharma, a Toronto based drug discovery company focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC Markets under the symbol $MSSTF.

In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.

*To learn more about Mindset Pharma, visit their website: MindsetPharma.com

Have you heard about our new community?

We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.

Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.

Sign Up Here